

# Journal Pre-proof

ResTORing barrier function in the skin

Jocelyn Wang, PhD, Mark H. Kaplan, PhD, Kai Yang, PhD

PII: S0091-6749(19)31328-4

DOI: <https://doi.org/10.1016/j.jaci.2019.10.007>


Reference: YMAI 14221

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 27 August 2019

Revised Date: 5 October 2019

Accepted Date: 11 October 2019



Please cite this article as: Wang J, Kaplan MH, Yang K, ResTORing barrier function in the skin, *Journal of Allergy and Clinical Immunology* (2019), doi: <https://doi.org/10.1016/j.jaci.2019.10.007>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

## **ResTORing barrier function in the skin**

Jocelyn Wang<sup>1</sup>, PhD, Mark H. Kaplan<sup>1,2</sup>, PhD, Kai Yang, PhD<sup>1,2</sup>

<sup>1</sup> Department of Pediatrics and Herman B Wells Center for Pediatric Research  
Indiana University School of Medicine, Indianapolis, IN 46202

<sup>2</sup> Department of Microbiology and Immunology, Indiana University School of Medicine,  
Indianapolis, IN, 46202

Correspondence:

Mark H. Kaplan

Indiana University School of Medicine

1044 West Walnut St. Room 202, Indianapolis, IN 46202

Office: 317.278.3696

[mkaplan2@iu.edu](mailto:mkaplan2@iu.edu)

Footnotes:

The authors have no financial conflicts of interest.

Preparation of this editorial was supported by a PHS grant from the National Institutes of Health R01 AI095282. Support provided by the Herman B Wells Center was in part from the Riley Children's Foundation.

**Key Words:** mTORC2, atopic dermatitis, barrier function; lipid biosynthesis

The primary functions of the epidermis include water retention, thermal and pH homeostasis, and protecting against the entry of pathogenic microbes or toxic substances into the body<sup>1,2</sup>. Appropriate epidermal barrier formation relies on the progressive differentiation of keratinocytes from the proliferating cells within the basal cell layer to the terminally differentiated cornified layer or stratum corneum<sup>2</sup>. The stratum corneum is composed of keratin macrofibrils and crosslinked cornified envelopes encased in lipid bilayers. Filaggrin and lipids produced by epidermal granular cells control the assembly of a lipid-keratin matrix in forming this semi-permeable barrier. Defects in the integrity of the epidermal barrier may result in a variety of inflammatory skin disorders including atopic dermatitis (AD) and ichthyosis.

Ichthyosis is characterized by the presence of excessive amounts of dry, scaly, and thick skin surface. The etiology of the ichthyosis is attributed to the complex interplay between keratinocyte differentiation and metabolic dysregulation. Genetic and clinical evidence indicates that defective expression and function of genes involved in the filaggrin processing and lipid synthesis impair the epidermal barrier acquisition and drive the onset of ichthyosis<sup>1</sup>, resulting in water loss, entry of infectious microbes, and infiltration of inflammatory lymphocytes. From the developmental perspective, it has been proposed that balancing keratinocyte proliferation and differentiation is crucial for shaping the epidermal barrier formation and function. Yet how keratinocytes coordinate their differentiation and lipid metabolism in the formation and maintenance of epidermal barrier remains elusive.

As with most allergic diseases, AD is a multifactorial disease, and genetics plays a significant role in disease progression. Because AD is a T helper 2-biased disease, many predisposing genes are linked to immune responses<sup>3,4</sup>. Recent studies have also identified the critical role of fatty acids synthesis in epidermal barrier formation and homeostasis<sup>5,6</sup>. One of the best-known risk factor genes, the filaggrin (*FLG*) gene, encodes an epidermal differentiation protein that is critical in forming the lipid-keratin matrix and epidermal integrity<sup>3,4</sup>. Mutations in the *FLG* gene can cause ichthyosis vulgaris and are a strong risk factor for AD<sup>3,4</sup>. However, *FLG* mutations do not account for all AD cases, and not every carrier of a *FLG* mutation develops AD. Therefore, the underlying molecular mechanisms that regulate epidermal barrier function remain incompletely defined.

The mechanistic target of rapamycin (mTOR) is an evolutionally conserved serine-threonine kinase that functions via two multiprotein complexes<sup>7</sup>, namely mTORC1 and mTORC2, characterized by the obligate proteins Raptor and Rictor, respectively. As a central node in cellular metabolism and cell growth, these mTOR complexes dictate the cell fate decision and function of a variety of cells through coupling proliferation and differentiation in response to microenvironmental cues. In contrast to extensive studies of mTOR complexes in T cells<sup>8</sup>, it is only now beginning to be understood how mTOR signaling regulates the epidermal barrier formation. Recent studies reveal that mTORC1 is crucial for keratinocyte proliferation and the early epidermal differentiation program<sup>9</sup>. In this issue of Journal of Allergy and Clinical Immunology, Ding et al show that

mTORC2 signaling controls the terminal differentiation and function of keratinocytes in the late stage of epidermal barrier formation (Figure 1)<sup>10</sup>.

Previous studies by Ding et al demonstrated that mTOR signaling is indispensable for the epidermal barrier formation<sup>9</sup>, albeit with differential roles defined for mTORC1 and mTORC2. By crossing mice carrying loxP-flanked target alleles (*Mtor*<sup>fl/fl</sup>, *Rptor*<sup>fl/fl</sup> or *Rictor*<sup>fl/fl</sup>) with human keratin 14 (K14) Cre recombinase transgenic mice, Ding et al were able to respectively abolish complete mTOR signaling, mTORC1 activation, or mTORC2 activation specifically in the epidermis<sup>9</sup>. Deletion of *Mtor* in mouse epidermis (mTOR<sup>EKO</sup>) resulted in newborns with defective epidermal barrier function that succumb to death shortly after birth<sup>9</sup>. They also demonstrated that mTORC1 and mTORC2 have distinct functions in maintaining healthy epidermal differentiation and formation. Newborn mice without Raptor displayed a similar phenotype with the mTOR<sup>EKO</sup> mice. However, mice with deletion of Rictor in the epidermis (Ric<sup>EKO</sup>) were able to survive despite abnormal skin development<sup>9</sup>. In the current study, Ding et al follow up on their initial findings with more detailed experiments investigating the precise mechanism by which mTORC2 regulates epidermal barrier formation<sup>10</sup>.

Using Ric<sup>EKO</sup> mice, Ding et al demonstrate that disruption of mTORC2 function alters normal epidermal formation. Ric<sup>EKO</sup> mice develop an ichthyosis-like phenotype at birth with reduced epidermal thickness and enhanced trans-epidermal water loss, which is similar to what is observed in human patients<sup>4</sup>. By RNA-sequencing of epidermis from wild type and Ric<sup>EKO</sup> E19.5 embryos, they reveal that many genes involved in keratinization, wound repair and keratinocyte differentiation are upregulated in the mutants, while immune regulating and lipid metabolism genes are downregulated. These findings suggest that dysfunctional mTORC2 promotes compensatory repair pathways and that lipid metabolism might be critical in epidermal formation.

To begin to address the role of lipid metabolism in regulating epidermal development, Ding et al<sup>10</sup> measure the lipid content in epidermis and show that there are decreased, and that there are altered lipid contents in several layers of epidermis. Furthermore, they show that mice with Rictor-deficient epidermis have altered proteolytic activity resulting in lower amounts of filaggrin monomers despite comparable levels of filaggrin mRNA and profilaggrin protein with controls. A direct link between mTORC2 function and filaggrin processing is established through complementation of the filaggrin processing defect in Ric<sup>EKO</sup> primary keratinocyte culture following Akt-Ser473 phosphorylation. Ric<sup>EKO</sup> mice also demonstrated altered immune cell profiles, including more CD4<sup>+</sup> T cell and fewer  $\gamma\delta$  T cells in their epidermis. With defective mTORC2 function and inappropriate immune cell compositions, Ric<sup>EKO</sup> mice respond poorly to the hapten DNFB. They also upregulate stress and proinflammatory genes in their ear skin in response to DNFB.

Collectively, Ding et al<sup>10</sup> demonstrate a distinctive role of mTORC2 in regulating intact skin barrier function. The animal model they chose parallels several hallmarks in human AD patients, including altered skin morphology and disrupted immune cell compositions, which suggest that their findings can be potentially translated to human studies. Among

the two complexes of mTOR, mTORC1 has been studied more extensively due to its responsiveness to acute treatment of rapamycin<sup>7</sup>. However, more and more effort has been devoted to investigating the importance of mTORC2 in cellular regulation and disease progression. Ding et al<sup>10</sup> conduct the first study to demonstrate that mTORC2 enforces the AKT-dependent filaggrin processing and orchestrates de novo lipid synthesis in keratinocytes. These processes shape the immune cell composition in the skin at steady state and its immune responses to allergens. These results indicate that dysfunctional mTORC2 could be another risk factor for skin diseases. Hence, carriers of mutations in mTORC2 could have higher risk of developing skin diseases. Certain cancer treatments also inhibit mTOR activities, which might compromise patients' skin integrity<sup>7</sup>. Combined therapy should be designed carefully to manage this potential side effect. Further studies are warranted to examine how mTORC2-dependent signaling regulates lipid metabolism. Moreover, the relevant ligands that activate mTORC2-dependent signaling have not been defined, and whether other environmental signals such as the epidermal microbiome, detergents, or particulate matter and pollution play a role in activating mTOR has not been tested. mTORC2 regulates many interacting pathways that are druggable and could serve as potentially novel therapeutic targets to reestablish epidermal barrier integrity and improve the treatment for common skin disorders<sup>7</sup>. Hence, identifying the roles of mTORC2-regulated metabolic networks in skin disease development has become the next pressing question.

1. Segre, J.A. **Epidermal barrier formation and recovery in skin disorders.** *J Clin Invest.* 2006;116:1150-1158.
2. Natsuga, K. **Epidermal barriers.** *Cold Spring Harb Perspect Med.* 2014;4:a018218.
3. Kubo, A., Nagao, K., Amagai, M. **Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases.** *J Clin Invest.* 2012;122:440-447.
4. Weidinger, S., Novak, N. **Atopic dermatitis.** *Lancet.* 2016;387:1109-1122.
5. Aldahmesh, M.A., Mohamed, J.Y., Alkuraya, H.S., Verma, I.C., Puri, R.D., Alaiya, A.A., et al. **Recessive mutations in ELOVL4 cause ichthyosis, intellectual disability, and spastic quadriplegia.** *Am J Hum Genet.* 2011;89:745-750.
6. Ilic, D., Bollinger, J.M., Gelb, M., Mauro, T.M. **SPLA2 and the epidermal barrier.** *Biochim Biophys Acta - Mol Cell Biol Lipids.* 2014;1841:416-421.
7. Saxton, R.A., Sabatini, D.M. **mTOR Signaling in Growth, Metabolism, and Disease.** *Cell.* 2017;168:960-976.
8. Chapman, N.M., Boothby, M.R., Chi, H. **Metabolic coordination of T cell quiescence and activation.** *Nat Rev Immunol.* August 2019:Epub ahead of print.
9. Ding, X., Bloch, W., Iden, S., Rüegg, M.A., Hall, M.N., Leptin, M., et al. **mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation.** *Nat Commun.* 2016;7:13226.
10. Ding, X., Willenborg, S., Bloch, W., Wickström, S.A., Wagle, P., Brodesser, S., et al. **Epidermal mTORC2 controls lipid synthesis and filaggrin processing in epidermal barrier formation.** *J Allergy Clin Immunol.* 2019;this issue.

*Microbiota, particulate matter, pollution, detergents, other environmental agents*

